10-K/A: Jaguar Health Files Amendment to 10-K, Discloses Executive and Director Compensation Details

Sentiment:

Annual Report Amendment 15 April 2025 4:00 PM

Jaguar Health amends its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Capital raiseThe company entered into securities purchase agreements for a private placement of approximately $3.4 million aggregate principal amount of convertible promissory notes.The Notes bear interest at a rate 6% per annum with maturity of three months after issuance and are subject to restrictive covenants.The Notes are immediately convertible, at each holders option, into an aggregate of 622,598 shares (the Conversion Shares) of the Companys voting common stock at a conversion price of $5.535 per share for Investors who are not an officer, director, employee or consultant (collectively, an Insider) of the Company and $5.555 per share for the Investors that are not Insiders.As an inducement to enter into the Securities Purchase Agreement, the Investors will receive warrants to purchase up to an aggregate of 622,598 shares of common stock (the Warrant Shares) with an initial exercise price equal to $5.41 per share for Investors who are not Insiders, and $5.43 per share for Investors who are Insiders.

Summary

Jaguar Health, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K/A for the year ended December 31, 2024.
The amendment includes information previously omitted from the Original Form 10-K regarding Part III, Items 10 through 14, which cover directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
The company did not file a definitive proxy statement within 120 days of December 31, 2024, necessitating this amendment.
As of March 31, 2025, Jaguar Health had 674,043 shares of voting common stock outstanding.
The aggregate market value of the registrant's common stock held by non-affiliates as of June 30, 2024, was approximately $28 million.
The board of directors has determined that James J. Bochnowski, John Micek III, Jonathan B. Siegel, and Anula Jayasuriya are independent directors.
The company's executive officers include Lisa Conte (CEO), Pravin Chaturvedi (Chief Scientific Officer), Carol Lizak (CFO), Steve King (Chief Sustainable Supply, Ethnobotanical Research, and IP Officer), and Jonathan Wolin (Chief of Staff, Chief Compliance Officer, and General Counsel).
The annual base salaries for the executive officers were increased effective October 1, 2024: Lisa Conte to $600,005, Dr. King to $367,369, Dr. Chaturvedi to $484,585, and Mr. Wolin to $412,777.
The company's clawback policy allows for the recovery of certain incentive-based compensation from current and former executive officers in the event of a restatement of consolidated financial statements.
The company engaged in several related-person transactions, including exchanges of common stock for royalty interest reductions with Iliad and Streeterville.
The company entered into securities purchase agreements for a private placement of approximately $3.4 million aggregate principal amount of convertible promissory notes.
Several directors, executive officers, and related parties participated in the private placement.
RBSM LLP served as the independent registered public accounting firm for the fiscal years ended December 31, 2022, 2023, and 2024, with audit fees of $250,000, $380,000, and $465,500, respectively.

Sentiment

Score: 5

Explanation: The document is primarily factual, providing required disclosures. The sentiment is neutral, with some potential concerns arising from related-party transactions and reliance on private placements.

Positives

The board of directors is comprised of a majority of independent directors, ensuring objective oversight.
The company has a clawback policy in place to recover incentive-based compensation in the event of financial restatements.
The company is actively managing its debt through exchanges of stock for royalty interest reductions.

Negatives

The company had to amend its annual report due to the omission of required information.
The company has engaged in multiple related-party transactions, which may raise concerns about potential conflicts of interest.
The company is relying on private placements to raise capital, which may be dilutive to existing shareholders.

Risks

Related-party transactions could potentially lead to conflicts of interest and may not always be on terms most favorable to the company.
Reliance on private placements for funding can result in dilution for existing shareholders.
The company's ability to meet its obligations under the convertible promissory notes depends on its financial performance and ability to raise additional capital.

Future Outlook

The company intends to file a definitive proxy statement at a later date, which will include additional information related to the topics covered in this amendment and additional information not required by Part III, Items 10 through 14 of Form 10-K.

Industry Context

The disclosure of executive compensation and corporate governance practices is a standard requirement for publicly traded companies, ensuring transparency and accountability to shareholders.

Comparison to Industry Standards

The executive compensation packages appear to be within the range of similar small-cap biotechnology companies, but a detailed benchmarking analysis would be required to confirm this.
The board independence aligns with Nasdaq requirements, which mandate a majority of independent directors.
The related-party transactions are not uncommon in small-cap companies, but the terms and fairness should be carefully scrutinized.

Related Party Transactions

On January 29, 2024, the Company entered into an exchange agreement with Iliad pursuant to which the Company issued an aggregate of 5,333 shares of the Companys common stock to Iliad in exchange for $836,000 reduction in the outstanding balance of the October 2020 Royalty Interest.
Additionally, the Company entered into an exchange agreement with Streeterville, which the Company issued an aggregate of 1,058 shares of the Companys common stock in exchange for $165,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
On February 27, 2024, pursuant to the PIPE Purchase Agreement, each of the PIPE investors entered into an exchange agreement with the Company (each, a PIPE Warrant Exchange Agreement and collectively, the PIPE Warrant Exchange Agreements).
Pursuant to the PIPE Warrant Exchange Agreements, the Company agreed to exchange the PIPE Warrants for shares of common stock at an exchange ratio of 1-for-2.5 (PIPE Warrant Exchange Transaction).
Upon completion of the PIPE Warrant Exchange Transaction, the Company exchanged the PIPE Warrants to purchase up to 5,023 shares of Common Stock for 12,558 shares of Common Stock (the PIPE Exchange Shares), and the PIPE Warrants were terminated.
On March 1, 2024, the Company entered into a privately negotiated exchange agreement with Streeterville (the Streeterville Exchange Agreement), pursuant to which the Company issued an aggregate of 179 shares of Series J Preferred Stock to Streeterville at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Streeterville Exchange Agreement, in exchange for the surrender of the March 2021 Purchase Agreement by Streeterville (the Streeterville Exchange Transaction).
On March 5, 2024, the Company issued 6,666 shares of the Companys common stock to Streeterville in exchange for the surrender and cancellation of 40 shares of Series J Perpetual Preferred Stock.
Subsequently, on March 19, 2024, the Company issued 5,556 shares of the Companys common stock in exchange for the surrender and cancellation of another 40 shares of Series J Perpetual Preferred Stock.
On June 7, 2024, the Company entered into an exchange agreement with Iliad, pursuant to which the parties agreed to partition $1,500,000 from the outstanding balance of the royalty interest dated October 8, 2020.
This reduced the outstanding balance of the original royalty interest.
The partitioned royalty was exchanged for 262 shares of the Companys common stock.
On July 15, 2024, the Company entered into a privately negotiated exchange agreement with Iliad pursuant to which the Company issued an aggregate of 18,200 shares of the Companys common stock to Iliad in exchange for a $1.9 million reduction in the outstanding balance of the original royalty interest.
The effect of the exchange was accounted for as a debt modification.
On July 18, 2024, the Company entered into a privately negotiated exchange agreement with Iliad pursuant to which the Company issued an aggregate of 8,000 shares of the Companys common stock to Iliad in exchange for $819,000 reduction in the outstanding balance of the original royalty interest.
The effect of the exchange was accounted for as a debt modification.
On January 28, 2025, the Company entered into a privately negotiated exchange agreement with Streeterville, pursuant to which the Company issued 51,600 shares of common stock to Streeterville in exchange for a $1,094,952 reduction in the outstanding balance of the royalty interest held by such holder.
On January 29, 2025, the Company and Napo entered into an amendment with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 issued by the Company and Napo to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.
Pursuant to the amendment, the maturity date of the note is extended to July 20, 2025.
On February 13, 2025, the Company and Napo entered into an amendment with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 issued by the Company and Napo to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.
Pursuant to the amendment, the maturity date of the note is further extended to January 20, 2026.
On February 14, 2025, the Company entered into a privately negotiated exchange agreement with Streeterville, pursuant to which the Company issued 14,000 shares of common stock to Streeterville in exchange for a $291,375 reduction in the outstanding balance of the Streetervilles royalty interest.
Lisa Conte, the Chief Executive Officer and President of the Company, invested approximately $50,000 in the Private Placement.
Pravin Chaturvedi, the Chief Scientific Officer and the Chair of Scientific Advisory Board of the Company, invested approximately $20,000 in the Private Placement.
Steven R. King, the Chief Sustainable Supply, Ethnobotanical Research, IP Officer and Secretary of the Company, invested approximately $20,000 in the Private Placement.
Jonathan S. Wolin, the Chief of Staff, Chief Compliance Officer, and General Counsel of the Company, invested approximately $50,000 in the Private Placement.
Carol Lizak, the Chief Financial Officer of the Company, invested approximately $30,000 in the Private Placement.
James J. Bochnowski, a member of the Companys board of directors, invested approximately $150,000 in the Private Placement.
Jonathan B. Siegel, a member of the Companys board of directors, invested approximately $50,000 in the Private Placement.
John Micek III, a member of the Companys board of directors, invested approximately $50,000 in the Private Placement.
Niccolo Caderni, a member of the board of directors of Napo Therapeutics S.p.A., a subsidiary of the Company incorporated in Italy, invested approximately $20,000 in the Private Placement.
Mark Johnson, an employee of the Company, invested approximately $25,000 in the Private Placement.
David F. Sesin, the Chief Manufacturing Officer of the Company, invested approximately $50,000 in the Private Placement.
Ian Wendt, the Chief Commercial Officer of the Company, invested approximately $20,000 in the Private Placement.
Streeterville, a beneficial owner of more than 5% of the Companys capital stock, invested approximately $250,000 in the Private Placement.

Stakeholder Impact

Shareholders may experience dilution due to the issuance of new shares in exchange for debt and in the private placement.
Executive officers and directors have a vested interest in the company's success, as evidenced by their participation in the private placement.
Employees may be impacted by the company's financial performance and ability to execute its business strategy.
Creditors are impacted by the company's debt management strategies, including exchanges of stock for royalty interest reductions.

Next Steps

The company intends to file a definitive proxy statement at a later date.
The company will need to manage its obligations under the convertible promissory notes issued in the private placement.

Key Dates

Date	Description
2020-10-08	Date of original royalty interest agreement with Iliad.
2021-01-19	Date of secured promissory note issued to Streeterville.
2024-01-01	Start of the fiscal year ended December 31, 2024.
2024-01-29	Date of exchange agreement with Iliad for common stock issuance.
2024-02-27	Date of PIPE Purchase Agreement and PIPE Warrant Exchange Agreements.
2024-03-01	Date of Streeterville Exchange Agreement for Series J Preferred Stock issuance.
2024-03-05	Date of common stock issuance to Streeterville for Series J Preferred Stock surrender.
2024-03-19	Date of common stock issuance to Streeterville for Series J Preferred Stock surrender.
2024-06-07	Date of exchange agreement with Iliad to partition royalty interest.
2024-06-30	Date used for calculating the aggregate market value of the registrant's common stock held by non-affiliates.
2024-07-15	Date of exchange agreement with Iliad for common stock issuance.
2024-07-18	Date of exchange agreement with Iliad for common stock issuance.
2024-10-01	Effective date of salary increases for executive officers.
2024-12-31	End of the fiscal year ended December 31, 2024.
2025-01-28	Date of exchange agreement with Streeterville for common stock issuance.
2025-01-29	Date of amendment with Streeterville to the secured promissory note.
2025-02-13	Date of amendment with Streeterville to the secured promissory note.
2025-02-14	Date of exchange agreement with Streeterville for common stock issuance.
2025-03-26	Date of Securities Purchase Agreements for private placement.
2025-03-31	Date used for calculating the number of shares of the registrant's common stock outstanding.
2025-04-10	Date used for calculating beneficial ownership of shares of Common Stock.
2025-04-15	Date of the filing of the amendment.

Keywords

executive compensation, directors, corporate governance, related party transactions, audit fees, private placement, Jaguar Health, 10-K/A

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.